Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 + BYL719 + letrozole in advanced ER-positive breast cancer
2023-509511-84-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Mar 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of ribociclib, alpelisib and letrozole in breast cancer (5 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities in cycle 1, Safety and tolerability and 1 more. Planned start Mar 2014; status: authorised.
02
Drugs
ribociclibalpelisibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-509511-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509511-84-00.